Video

Ovarian Cancer Developments in 2017

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.

The year 2017 has been an important one for the ovarian cancer field. New drugs have been approved that give hope to people who have tried other therapies but whose cancer has come back.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, shares his thoughts on the exciting developments in his field. Three poly (ADP-ribose) polymerase (PARP) inhibitors were recently approved for people who have ovarian cancer which are administered orally, so they are convenient to take, and may be taken for a long time. He believes patients will benefit greatly from these drugs.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of Dr. Deville.
Image of man.
Image of kelly.
Robotic and minimally invasive kidney cancer surgery may reduce pain, shorten recovery time and preserve kidney function, according to Dr. Armine Smith.
Image of Doctor.
Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.
The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.
Image of Dr. Doug
Image of doctor.
Related Content